ClinicalTrials.gg
RecruitingNCT07571174Updated Sep 22, 2026

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

A Phase 1 interventional study of LY4256984 in Amyotrophic Lateral Sclerosis, sponsored by Eli Lilly and Company. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
54th of 72
32 · median 75
Started
2026
with 4 others
Phase 1
16 of 82
5 open now
Primary completion
2029-06
later than 20 of 24 live
Registered
80th of 82
by date
Lead sponsor
4 of 82
Eli Lilly and Company

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 54th largest by planned enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 in phase 1, reaches primary completion later than 20 of the 24 other live ones, and was the 80th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants must meet eligibility criteria in the [L0U-MC-OLMP] screening protocol before entry into the treatment study.

Inclusion criteria

Inclusion Criteria:

  • Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA.

Exclusion criteria

Exclusion Criteria:

  • The participant has conditions that preclude a lumbar puncture (LP), such as:

    • A history of back pain, back pathology, and/or back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP.
    • Allergy to local anesthetics, such as lidocaine or its derivatives.
    • A local infection at the intended site of the LP.
    • Less than 100 giga per liter [(\<100 GI/L) is equivalent to 100,000 per cubic millimeter (100,000/mm³)] or clinically significant coagulation abnormality or significant active bleeding, or
    • Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    LY4256984

    LY4256984 administered intrathecally (IT)

    Drug: LY4256984

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline Up to Week 96

07

Study locations

2 of 11 sites recruiting
  • UZ Leuven
    Leuven, 3000, Belgium
    Not yet recruiting
    • Philip Van Damme · Principal investigator
  • Heritage Medical Research Clinic
    Calgary, T2N 4Z6, Canada
    Not yet recruiting
    • Theodore Mobach · Principal investigator
  • University Hospital - London Health Sciences Centre
    London, N6A 5A5, Canada
    Not yet recruiting
    • Christen Shoesmith · Principal investigator
  • McGill University Health Centre
    Montreal, H4A 3J1, Canada
    Recruiting
    • Angela Genge · Principal investigator
  • Sunnybrook Research Institute
    Toronto, M4N 3M5, Canada
    Recruiting
    • Agessandro Abrahao · Principal investigator
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, 23538, Germany
    Not yet recruiting
    • Julian Grosskreutz · Principal investigator
  • Universitätsmedizin Rostock
    Rostock, 18147, Germany
    Not yet recruiting
    • Andreas Hermann · Principal investigator
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
    Not yet recruiting
    • Jochen Weishaupt · Principal investigator
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
    Not yet recruiting
    • Leonard H. Berg · Principal investigator
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
    Not yet recruiting
    • MONICA POVEDANO PANADES · Principal investigator
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Not yet recruiting
    • Juan Vazquez-Costa · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2029, 37 months after the start.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 37 months is above that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartActual
May 14, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07571174
Responsible party
Sponsor
First posted
May 6, 2026
Start date
May 14, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 22, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
3176154559
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4256984

Start the discussion